D
Actinium Pharmaceuticals, Inc.
ATNM
$8.84
-$0.12-1.34%
D
Sell
1/24/2024Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 1/24/2024 due to an increase in the volatility index, valuation index and total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 1/24/2024 due to an increase in the volatility index, valuation index and total return index.
E
Sell
1/9/2024Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 1/9/2024 due to a decline in the valuation index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 1/9/2024 due to a decline in the valuation index and volatility index.
D
Sell
11/24/2023Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 11/24/2023 due to an increase in the total return index, volatility index and valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 11/24/2023 due to an increase in the total return index, volatility index and valuation index.
E
Sell
11/9/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 11/9/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 9.97 to 9.57.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 11/9/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 9.97 to 9.57.
D
Sell
11/3/2023Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 11/3/2023 due to an increase in the volatility index and valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 11/3/2023 due to an increase in the volatility index and valuation index.
E
Sell
10/19/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 10/19/2023 due to a decline in the total return index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 10/19/2023 due to a decline in the total return index and volatility index.
D
Sell
10/4/2023Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 10/4/2023 due to an increase in the valuation index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 10/4/2023 due to an increase in the valuation index and volatility index.
E
Sell
9/19/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 9/19/2023 due to a decline in the valuation index, volatility index and total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 9/19/2023 due to a decline in the valuation index, volatility index and total return index.
D
Sell
8/31/2023Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 8/31/2023 due to an increase in the valuation index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 8/31/2023 due to an increase in the valuation index and volatility index.
E
Sell
8/15/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 8/15/2023 due to a decline in the growth index, solvency index and volatility index. EBIT declined 35.03% from -$11.58M to -$15.64M, earnings per share declined from -$0.43 to -$0.579, and the quick ratio declined from 12.02 to 9.97.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 8/15/2023 due to a decline in the growth index, solvency index and volatility index. EBIT declined 35.03% from -$11.58M to -$15.64M, earnings per share declined from -$0.43 to -$0.579, and the quick ratio declined from 12.02 to 9.97.
D
Sell
8/10/2023Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 8/10/2023 due to an increase in the volatility index and valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 8/10/2023 due to an increase in the volatility index and valuation index.
E
Sell
7/26/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 7/26/2023 due to a decline in the total return index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 7/26/2023 due to a decline in the total return index and volatility index.
D
Sell
7/6/2023Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 7/6/2023 due to an increase in the valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 7/6/2023 due to an increase in the valuation index.
E
Sell
6/15/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 6/15/2023 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 93.84% from -$7.78M to -$15.08M, earnings per share declined from -$0.4177 to -$0.43, and EBIT declined 2.59% from -$11.29M to -$11.58M.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 6/15/2023 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 93.84% from -$7.78M to -$15.08M, earnings per share declined from -$0.4177 to -$0.43, and EBIT declined 2.59% from -$11.29M to -$11.58M.
D
Sell
3/14/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D+ on 3/14/2023 due to a noticeable decline in the total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D+ on 3/14/2023 due to a noticeable decline in the total return index.
D
Sell
2/28/2023Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 2/28/2023 due to an increase in the valuation index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 2/28/2023 due to an increase in the valuation index and volatility index.
D
Sell
2/23/2023Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
2/1/2023Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 2/1/2023 due to a decline in the valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 2/1/2023 due to a decline in the valuation index.
D
Sell
12/22/2022Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 12/22/2022 due to a major increase in the total return index, valuation index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 12/22/2022 due to a major increase in the total return index, valuation index and volatility index.
D
Sell
11/18/2022Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 11/18/2022 due to a decline in the growth index, valuation index and solvency index. Operating cash flow declined 120.47% from $27.92M to -$5.72M, the quick ratio declined from 18.52 to 13.39, and EBIT declined 24.83% from -$7.85M to -$9.8M.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 11/18/2022 due to a decline in the growth index, valuation index and solvency index. Operating cash flow declined 120.47% from $27.92M to -$5.72M, the quick ratio declined from 18.52 to 13.39, and EBIT declined 24.83% from -$7.85M to -$9.8M.
D
Sell
11/3/2022Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 11/3/2022 due to a major increase in the total return index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 11/3/2022 due to a major increase in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from E+ on 5/16/2022 due to a large increase in the growth index, volatility index and solvency index. Total revenue increased 3,986.96% from $23 to $940, earnings per share increased from -$0.3626 to -$0.2316, and EBIT increased 35.83% from -$8.05M to -$5.16M.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from E+ on 5/16/2022 due to a large increase in the growth index, volatility index and solvency index. Total revenue increased 3,986.96% from $23 to $940, earnings per share increased from -$0.3626 to -$0.2316, and EBIT increased 35.83% from -$8.05M to -$5.16M.
E
Sell
5/13/2022Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
E
Sell
5/1/2022Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index and valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index and valuation index.
D
Sell
4/20/2022Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, solvency index and volatility index. The quick ratio declined from 19.58 to 11.38.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, solvency index and volatility index. The quick ratio declined from 19.58 to 11.38.
D
Sell
11/15/2021Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 11/15/2021 due to an increase in the total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 11/15/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
10/23/2020Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 10/23/2020 due to a decline in the valuation index and solvency index. The quick ratio declined from 11.48 to 10.31.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 10/23/2020 due to a decline in the valuation index and solvency index. The quick ratio declined from 11.48 to 10.31.
D
Sell
10/22/2020Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 10/22/2020 due to an increase in the total return index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 10/22/2020 due to an increase in the total return index and volatility index.
D
Sell
9/1/2020Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 9/1/2020 due to a decline in the total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 9/1/2020 due to a decline in the total return index.
D
Sell
8/17/2020Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 8/17/2020 due to a large increase in the total return index, valuation index and solvency index. The quick ratio increased from 1.26 to 11.48, and debt to equity declined from 0.22 to 0.01.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 8/17/2020 due to a large increase in the total return index, valuation index and solvency index. The quick ratio increased from 1.26 to 11.48, and debt to equity declined from 0.22 to 0.01.
D
Sell
7/17/2020Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 7/17/2020 due to an increase in the volatility index and total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 7/17/2020 due to an increase in the volatility index and total return index.
D
Sell
7/2/2020Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 7/2/2020 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.13 to 0.22, the quick ratio declined from 1.73 to 1.26, and EBIT declined 22.65% from -$4.63M to -$5.68M.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 7/2/2020 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.13 to 0.22, the quick ratio declined from 1.73 to 1.26, and EBIT declined 22.65% from -$4.63M to -$5.68M.
D
Sell
6/11/2020Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 6/11/2020 due to an increase in the volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 6/11/2020 due to an increase in the volatility index.
D
Sell
5/27/2020Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 5/27/2020 due to a decline in the volatility index and total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 5/27/2020 due to a decline in the volatility index and total return index.
D
Sell
5/8/2020Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 5/8/2020 due to an increase in the total return index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 5/8/2020 due to an increase in the total return index and volatility index.
D
Sell
8/13/2019Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 8/13/2019 due to an increase in the solvency index and valuation index. The quick ratio increased from 1.7 to 3.77, and debt to equity declined from 0.1 to 0.03.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 8/13/2019 due to an increase in the solvency index and valuation index. The quick ratio increased from 1.7 to 3.77, and debt to equity declined from 0.1 to 0.03.
E
Sell
8/1/2019Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 8/1/2019 due to a decline in the total return index and volatility index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 8/1/2019 due to a decline in the total return index and volatility index.
D
Sell
7/17/2019Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 7/17/2019 due to an increase in the volatility index and valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 7/17/2019 due to an increase in the volatility index and valuation index.
E
Sell
5/15/2019Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 5/15/2019 due to a decline in the solvency index, valuation index and total return index. Debt to equity increased from 0.03 to 0.26, and the quick ratio declined from 2.26 to 1.7.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 5/15/2019 due to a decline in the solvency index, valuation index and total return index. Debt to equity increased from 0.03 to 0.26, and the quick ratio declined from 2.26 to 1.7.
D
Sell
5/8/2019Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 5/8/2019 due to an increase in the valuation index and total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 5/8/2019 due to an increase in the valuation index and total return index.
E
Sell
4/23/2019Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 4/23/2019 due to a decline in the volatility index, efficiency index and valuation index. Total capital declined 21.63% from $11.58M to $9.08M, and net income declined 2.79% from -$6.15M to -$6.32M.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 4/23/2019 due to a decline in the volatility index, efficiency index and valuation index. Total capital declined 21.63% from $11.58M to $9.08M, and net income declined 2.79% from -$6.15M to -$6.32M.
D
Sell
6/29/2017Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 6/29/2017 due to an increase in the volatility index and valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D- from E+ on 6/29/2017 due to an increase in the volatility index and valuation index.
E
Sell
6/14/2017Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 6/14/2017 due to a decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 4.54 to 3.18, total capital declined 28.51% from $18.01M to $12.88M, and net income declined 20.4% from -$6.7M to -$8.06M.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to E+ from D- on 6/14/2017 due to a decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 4.54 to 3.18, total capital declined 28.51% from $18.01M to $12.88M, and net income declined 20.4% from -$6.7M to -$8.06M.
D
Sell
3/11/2016Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, growth index and total return index. Earnings per share declined from -$0.0959 to -$0.1579, operating cash flow declined 13.29% from -$3.5M to -$3.96M, and EBIT declined 6.04% from -$4.64M to -$4.92M.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, growth index and total return index. Earnings per share declined from -$0.0959 to -$0.1579, operating cash flow declined 13.29% from -$3.5M to -$3.96M, and EBIT declined 6.04% from -$4.64M to -$4.92M.
D
Sell
2/26/2016Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 2/26/2016 due to a decline in the valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 2/26/2016 due to a decline in the valuation index.
D
Sell
2/11/2016Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 2/11/2016 due to an increase in the valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 2/11/2016 due to an increase in the valuation index.
D
Sell
1/12/2016Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 1/12/2016 due to a decline in the valuation index and total return index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 1/12/2016 due to a decline in the valuation index and total return index.
D
Sell
12/28/2015Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 12/28/2015 due to a noticeable increase in the solvency index, growth index and valuation index. The quick ratio increased from 8.51 to 11.49.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 12/28/2015 due to a noticeable increase in the solvency index, growth index and valuation index. The quick ratio increased from 8.51 to 11.49.
D
Sell
12/24/2014Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 12/24/2014 due to a decline in the volatility index, total return index and valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 12/24/2014 due to a decline in the volatility index, total return index and valuation index.
D
Sell
12/9/2014Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 12/9/2014 due to an increase in the volatility index and valuation index.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 12/9/2014 due to an increase in the volatility index and valuation index.
D
Sell
10/31/2014Downgrade
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 10/31/2014 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 1.32 to 1.15.
Actinium Pharmaceuticals, Inc. (ATNM) was downgraded to D from D+ on 10/31/2014 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 1.32 to 1.15.
D
Sell
10/1/2014Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 10/1/2014 due to an increase in the total return index, growth index and solvency index. The quick ratio increased from 0.29 to 1.32, debt to equity declined from -0.01 to 0.01, and EBIT increased 6.92% from -$4.14M to -$4.42M.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D+ from D on 10/1/2014 due to an increase in the total return index, growth index and solvency index. The quick ratio increased from 0.29 to 1.32, debt to equity declined from -0.01 to 0.01, and EBIT increased 6.92% from -$4.14M to -$4.42M.
D
Sell
4/1/2014Upgraded
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 4/1/2014 due to a large increase in the efficiency index, valuation index and volatility index. Net income increased 313.81% from -$1.42M to -$5.88M.
Actinium Pharmaceuticals, Inc. (ATNM) was upgraded to D from D- on 4/1/2014 due to a large increase in the efficiency index, valuation index and volatility index. Net income increased 313.81% from -$1.42M to -$5.88M.
AMEX
05/06/2024 4:00PM Eastern
Quotes delayed
